The Synthesis and Biological Evaluation of Indolactam Alkaloids

Manuel Mendoza; Ryan Eom; Celeste Salas; Jeremy Haynes-Smith; Kelvin L. Billingsley

doi:10.1055/s-0039-1690198

Synthesis, Inhaltsverzeichnis

Synthesis 2019; 51(23): 4443-4451
DOI: 10.1055/s-0039-1690198

paper

The Synthesis and Biological Evaluation of Indolactam Alkaloids

Manuel Mendoza

^aDepartment of Chemistry and Biochemistry, California State University Fullerton, Fullerton, CA 92831, USA eMail: kbillingsley@fullerton.edu

,

Ryan Eom

^bDepartment of Chemistry and Chemical Biology, Cornell University, Ithaca, NY 14853, USA

,

Celeste Salas

^aDepartment of Chemistry and Biochemistry, California State University Fullerton, Fullerton, CA 92831, USA eMail: kbillingsley@fullerton.edu

,

Jeremy Haynes-Smith

^cDepartment of Chemistry and Biochemistry, San Francisco State University, San Francisco, CA 94132, USA

,

Kelvin L. Billingsley ∗

^aDepartment of Chemistry and Biochemistry, California State University Fullerton, Fullerton, CA 92831, USA eMail: kbillingsley@fullerton.edu

› Institutsangaben

Abstract

Alle Artikel dieser Rubrik

Abstract

In this work, we execute a general synthetic strategy to access novel indolactam alkaloids, which are agonists of protein kinase C. This protocol allowed for the most efficient reported syntheses of indolactam V (ILV) stereoisomers, while also affording the large-scale production of natural product (–)-ILV. Structure–activity studies were conducted with these compounds to elucidate the elements necessary to promote PKC-mediated cellular response. EC₅₀ measurements in leukemia and lymphoma cell lines, as well as molecular docking analyses with the PKCδ C1B domain, provided the foundation for these studies. A distinct correlation between in vitro activity and the conformation of the macrocyclic lactam ring was discovered, which can guide design efforts for therapeutics that target the PKC regulatory domain.

Key words

natural products - synthesis - indolactams - amino acids - protein kinase C

Volltext

Referenzen

References
1 Protein Kinase C . Dekker LV. Springer; New York: 2004

2a Whiteside CI, Dlugosz JA. Am. J. Physiol. 2002; 282: F975
2b Vlahos CJ, McDowell SA, Clerk A. Nat. Rev. Drug Discovery 2003; 2: 99
2c Greenberg DA. Proc. Natl. Acad. Sci. U. S. A. 2006; 103: 7943
2d Etcheberrigaray R, Tan M, Dewachter I, Kuiperi C, Van der Auwera I, Wera S, Qiao L, Bank B, Nelson TJ, Kozikowski AP, Van Leuven F, Alkon DL. Proc. Natl. Acad. Sci. U. S. A. 2004; 101: 11141

3 Griner EM, Kazanietz MG. Nat. Rev. Cancer 2007; 7: 281

4a Carter CA, Kane CJ. M. Curr. Med. Chem. 2004; 11: 2883
4b O’Brian CA, Ward NE, Stewart JR, Chu F. Cancer Metastasis Rev. 2001; 20: 95
4c Battaini F. Pharmacol. Res. 2001; 44: 353
4d Ma D. Curr. Med. Chem. 2001; 8: 191
4e Marquez VE, Blumberg PM. Acc. Chem. Res. 2003; 36: 434

5a Endo Y, Takehana S, Ohno M, Driedger PE, Stabel S, Mizutani MY, Tomioka N, Itai A, Shudo K. J. Med. Chem. 1998; 41: 1476
5b Wender PA, Koehler KF, Sharkey NA, Dell’Aquila ML, Blumberg PM. Proc. Natl. Acad. Sci. U. S. A. 1986; 83: 4214

6 Fujiki H, Sugimura T. Adv. Cancer Res. 1987; 49: 223

7a Endo Y, Shudo K, Furuhata K, Ogura H, Sakai S, Aimi N, Hitotsuyanagi Y, Koyama Y. Chem. Pharm. Bull. 1984; 32: 358
7b Endo Y, Shudo K, Itai A, Hasegawa M, Sakai S. Tetrahedron 1986; 42: 5905
7c de Laszlo SE, Ley SV, Porter RA. J. Chem. Soc., Chem. Commun. 1986; 344
7d Mascal M, Moody CJ. J. Chem. Soc., Chem. Commun. 1988; 589
7e Masuda T, Nakatsuka S, Goto T. Agric. Biol. Chem. 1989; 53: 2257
7f Kogan TP, Somers TC, Venuti MC. Tetrahedron 1990; 46: 6623
7g Mascal M, Moody CJ, Slawin AM. Z, Williams D. J. Chem. Soc., Perkin Trans. 1 1992; 823
7h Semmelhack MF, Rhee HA. Tetrahedron Lett. 1993; 34: 1395
7i Quick J, Saha B, Driedger PE. Tetrahedron Lett. 1994; 35: 8549
7j Bronner SM, Goetz AE, Garg NK. J. Am. Chem. Soc. 2011; 133: 3832
7k Xu Z, Zhang F, Zhang L, Jia Y. Org. Biomol. Chem. 2011; 9: 2512
7l Nathel NF. F, Shah TK, Bronner SM, Garg NK. Chem. Sci. 2014; 5: 2184
7m Noji T, Okano K, Tokuyama H. Tetrahedron 2015; 71: 3833
7n Haynes-Smith J, Diaz I, Billingsley KL. Org. Lett. 2016; 18: 2008
7o Nakamura H, Yasui K, Kanda Y, Baran PS. J. Am. Chem. Soc. 2019; 141: 1494

8 Fujiki H, Suganuma M, Nakayasu M, Tahira T, Endo Y, Shudo K, Sugimura T. Gann 1984; 75: 866

9a Endo Y, Shudo K, Okamoto T. Chem. Pharm. Bull. 1982; 30: 3457
9b Nakatsuka S.-i, Masuda T, Sakai K, Goto T. Tetrahedron Lett. 1986; 27: 5735
9c Mari M, Bartoccini F, Piersanti G. J. Org. Chem. 2013; 78: 7727

10 Choi DW, Hartley DM. US5292765A, 1994
11 Kawai T, Ichinose T, Endo Y, Shudo K, Itai A. J. Med. Chem. 1992; 35: 2248
12 Mendoza M, Rao N, Tran U, Castaneda C, Billingsley KL. Tetrahedron 2019; 75: 4337
13 Angelini E, Balsamini C, Bartoccini F, Lucarini S, Piersanti G. J. Org. Chem. 2008; 73: 5654

14a Kortmansky J, Schwartz GK. Cancer Invest. 2003; 21: 924
14b Kollár P, Rajchard J, Balounová Z, Pazourek J. Pharm. Biol. 2014; 52: 237

15 Nakagawa Y, Irie K, Yanagita RC, Ohigashi H, Tsuda K. J. Am. Chem. Soc. 2005; 127: 5746
16 Irie K, Isaka T, Iwata Y, Yanai Y, Nakamura Y, Koizumi F, Ohigashi H, Wender PA, Satomi Y, Nishino H. J. Am. Chem. Soc. 1996; 118: 10733
17 Kawai T, Ichinose T, Takeda M, Tomioka N, Endo Y, Yamaguchi K, Shudo K, Itai A. J. Org. Chem. 1992; 57: 6150
18 Hesek D, Lee M, Noll BC, Fisher JF, Mobashery S. J. Org. Chem. 2009; 74: 2567

Zusatzmaterial

Supporting Information